Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse.
Addiction is a complex process that relies on the ability of an organism to integrate positive and negative properties of drugs of abuse. Therefore, studying the reinforcing as well as aversive components of drugs of abuse in a single model system will enable us to understand the role of final common mediators, such as cAMP response element-binding protein (CREB), in the addiction process. To this end, we analyzed mice with a mutation in the alpha and Delta isoforms of the CREB gene. Previously we have shown that CREB(alphaDelta) mutant mice in a mixed genetic background show attenuated signs of physical dependence, as measured by the classic signs of withdrawal. We have generated a uniform genetically stable F1 hybrid (129SvEv/C57BL/6) mouse line harboring the CREB mutation. We have found the functional activity of CREB in these F1 hybrid mice to be dramatically reduced compared with their wild-type littermates. These mice maintain a reduced withdrawal phenotype after chronic morphine. We are now poised to examine a number of complex behavioral phenotypes related to addiction in a well defined CREB-deficient mouse model. We demonstrate that the aversive properties of morphine are still present in CREB mutant mice despite a reduction of physical withdrawal. On the other hand, these mice do not respond to the reinforcing properties of morphine in a conditioned place preference paradigm. In contrast, CREB mutant mice demonstrate an enhanced response to the reinforcing properties of cocaine compared with their wild-type controls in both conditioned place preference and sensitization behaviors. These data may provide the first paradigm for differential vulnerability to various drugs of abuse.
Walters
C L
CL
Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Blendy
J A
JA
D000483:Alleles; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000378:metabolism; D003042:Cocaine / Q000008:administration & dosage; D019970:Cocaine-Related Disorders / Q000235:genetics / Q000378:metabolism*; D003213:Conditioning, Psychological / Q000187:drug effects; D003433:Crosses, Genetic; D017362:Cyclic AMP Response Element-Binding Protein / Q000235:genetics* / Q000378:metabolism*; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D004343:Drug Implants; D007274:Injections, Intraperitoneal; D051379:Mice; D008815:Mice, Inbred Strains; D008817:Mice, Mutant Strains; D009020:Morphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D009021:Morphine Dependence / Q000235:genetics / Q000378:metabolism*; D009042:Motivation; D009043:Motor Activity / Q000187:drug effects; D009292:Narcotic Antagonists / Q000494:pharmacology; D010641:Phenotype; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D012054:Reinforcement, Psychology; D020218:Response Elements / Q000502:physiology; D013037:Spatial Behavior / Q000187:drug effects / Q000502:physiology
D017362:Cyclic AMP Response Element-Binding Protein; D004343:Drug Implants; D009292:Narcotic Antagonists; D020033:Protein Isoforms; D009020:Morphine; D003042:Cocaine